ArticleAntimicrobial agents and chemotherapy2015
The resistome of Pseudomonas aeruginosa in relationship to phenotypic susceptibility.
Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 155 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
155 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Large-scale assessment of antimicrobial resistance marker databases for genetic phenotype prediction: a systematic review.The Journal of antimicrobial chemotherapy · 2020Pooled it
- Multidrug resistant Pseudomonas aeruginosa in Estonian hospitals.BMC infectious diseases · 2018Trial
- Phenotypic and biochemical characterization of the class C β-lactamase, PAC-1.The Journal of antimicrobial chemotherapy · 2026Article
- Beyond Resistance Genes:Life (Basel, Switzerland) · 2026Review
- Genomic comparison and phenotypic characterization ofmSystems · 2026Article
- AMR-GNN: a multi-representation graph neural network framework to enable genomic antimicrobial resistance prediction.Nature communications · 2026Article
- Defence systems drive accessory genome interactions inISME communications · 2026Article
- First nationwide survey onAntimicrobial agents and chemotherapy · 2025Article
- Deciphering the emergence of mutations in Pseudomonas aeruginosa after ceftolozane/tazobactam treatment and evaluating therapeutic alternatives.BMC microbiology · 2025Article
- Mapping genetic and phenotypic diversity ofbioRxiv : the preprint server for biology · 2025Article
- New Insights inAntibiotics (Basel, Switzerland) · 2025Article
- Strain-specific variation in the complement resistome ofInfection and immunity · 2025Article
- Whole Genome Analysis of Ocular Pseudomonas aeruginosa Isolates Reveals Genetic Diversity.Investigative ophthalmology & visual science · 2025Article
- Functional and Pangenomic Exploration of Roc Two-Component Regulatory Systems Identifies Novel Players Across Pseudomonas Species.Molecular microbiology · 2025Article
- Genomic characterization ofMicrobial genomics · 2025Article
- Molecular epidemiological study of Pseudomonas aeruginosa strains isolated from hospitals in Brazil by MLST and CRISPR/Cas system analysis.Molecular genetics and genomics : MGG · 2025Article
- Genomic Characterization of Extremely Antibiotic-Resistant Strains ofBiotech (Basel (Switzerland)) · 2025Article
- Article
- Genotypic and phenotypic analyses of two distinct sets ofJournal of medical microbiology · 2025Article
- Genomic Epidemiology of Pseudomonas aeruginosa Sequence Type 111.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
95 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many clinical isolates of Pseudomonas aeruginosa cause infections that are difficult to eradicate due to their resistance to a wide variety of antibiotics. Key genetic determinants of resistance were identified through genome sequences of 390 clinical isolates of P. aeruginosa, obtained from diverse geographic locations collected between 2003 and 2012 and were related to microbiological susceptibility data for meropenem, levofloxacin, and amikacin. β-Lactamases and integron cassette arrangements were enriched in the established multidrug-resistant lineages of sequence types ST111 (predominantly O12) and ST235 (O11). This study demonstrates the utility of next-generation sequencing (NGS) in defining relevant resistance elements and highlights the diversity of resistance determinants within P. aeruginosa. This information is valuable in furthering the design of diagnostics and therapeutics for the treatment of P. aeruginosa infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.